BACKGROUND: To reduce mortality, women with a family history of breast cancer are often screened with mammography before age 50 years. Additional magnetic resonance imaging (MRI) improves sensitivity and is cost-effective for BRCA1/2 mutation carriers. However, for women with a family history without a proven mutation, cost-effectiveness is unclear. METHODS: We evaluated data of the largest prospective MRI screening study (MRISC). Between 1999 and 2007, 1597 women (8370 woman-years at risk) aged 25 to 70 years with an estimated cumulative lifetime risk of 15% to 50% for breast cancer were screened with clinical breast examination every 6 months and with annual mammography and MRI. We calculated the cost per detected and treated breast cancer. After incorporating MRISC data into a microsimulation screening analysis model (MISCAN), different schemes were evaluated, and cost per life-year gained (LYG) was estimated in comparison with the Dutch nationwide breast cancer screening program (biennial mammography from age 50 to 75 years). All statistical tests were two-sided. RESULTS: Forty-seven breast cancers (9 ductal carcinoma in situ) were detected. Screening with additional MRI costs $123 672 (€93 639) per detected breast cancer. In increasing age-cohorts, costs per detected and treated breast cancer decreased, but, unexpectedly, the percentage of MRI-only detected cancers increased. Screening under the MRISC-scheme from age 35 to 50 years was estimated to reduce breast cancer mortality by 25% at $134 932 (€102 164) per LYG (3.5% discounting) compared with 17% mortality reduction at $54 665 (€41 390) per LYG with mammography only. CONCLUSIONS: Screening with MRI may improve survival for women with familial risk for breast cancer but is expensive, especially in the youngest age categories.
BACKGROUND: To reduce mortality, women with a family history of breast cancer are often screened with mammography before age 50 years. Additional magnetic resonance imaging (MRI) improves sensitivity and is cost-effective for BRCA1/2 mutation carriers. However, for women with a family history without a proven mutation, cost-effectiveness is unclear. METHODS: We evaluated data of the largest prospective MRI screening study (MRISC). Between 1999 and 2007, 1597 women (8370 woman-years at risk) aged 25 to 70 years with an estimated cumulative lifetime risk of 15% to 50% for breast cancer were screened with clinical breast examination every 6 months and with annual mammography and MRI. We calculated the cost per detected and treated breast cancer. After incorporating MRISC data into a microsimulation screening analysis model (MISCAN), different schemes were evaluated, and cost per life-year gained (LYG) was estimated in comparison with the Dutch nationwide breast cancer screening program (biennial mammography from age 50 to 75 years). All statistical tests were two-sided. RESULTS: Forty-seven breast cancers (9 ductal carcinoma in situ) were detected. Screening with additional MRI costs $123 672 (€93 639) per detected breast cancer. In increasing age-cohorts, costs per detected and treated breast cancer decreased, but, unexpectedly, the percentage of MRI-only detected cancers increased. Screening under the MRISC-scheme from age 35 to 50 years was estimated to reduce breast cancer mortality by 25% at $134 932 (€102 164) per LYG (3.5% discounting) compared with 17% mortality reduction at $54 665 (€41 390) per LYG with mammography only. CONCLUSIONS: Screening with MRI may improve survival for women with familial risk for breast cancer but is expensive, especially in the youngest age categories.
Authors: John T Brinton; Lora D Barke; Mary E Freivogel; Tiffany C Talley; Michelle D Lexin; Alicia L Drew; Rachel B Beam; Deborah H Glueck Journal: Health Commun Date: 2017-02-03
Authors: Stephane Zervoudis; George Iatrakis; Eirini Tomara; Anastasia Bothou; George Papadopoulos; George Tsakiris Journal: World J Clin Oncol Date: 2014-08-10
Authors: H Amarens Geuzinge; Inge-Marie Obdeijn; Emiel J T Rutgers; Sepideh Saadatmand; Ritse M Mann; Jan C Oosterwijk; Rob A E M Tollenaar; Diderick B W de Roy van Zuidewijn; Marc B I Lobbes; Martijne van 't Riet; Maartje J Hooning; Margreet G E M Ausems; Claudette E Loo; Jelle Wesseling; Ernest J T Luiten; Harmien M Zonderland; Cees Verhoef; Eveline A M Heijnsdijk; Madeleine M A Tilanus-Linthorst; Harry J de Koning Journal: JAMA Oncol Date: 2020-09-01 Impact factor: 31.777
Authors: Deirdre A Hill; Jennifer S Haas; Robert Wellman; Rebecca A Hubbard; Christoph I Lee; Jennifer Alford-Teaster; Karen J Wernli; Louise M Henderson; Natasha K Stout; Anna N A Tosteson; Karla Kerlikowske; Tracy Onega Journal: J Gen Intern Med Date: 2017-12-06 Impact factor: 5.128
Authors: Valérie D V Sankatsing; Karolina Juraniec; Sabine E Grimm; Manuela A Joore; Ruud M Pijnappel; Harry J de Koning; Nicolien T van Ravesteyn Journal: Radiology Date: 2020-08-04 Impact factor: 11.105
Authors: Ryan W Woods; Lonie R Salkowski; Mai Elezaby; Elizabeth S Burnside; Roberta M Strigel; Amy M Fowler Journal: Clin Imaging Date: 2019-11-28 Impact factor: 1.605
Authors: Andrew McGuire; James A L Brown; Carmel Malone; Ray McLaughlin; Michael J Kerin Journal: Cancers (Basel) Date: 2015-05-22 Impact factor: 6.639